Your patients and/or their caregivers will likely have questions about how to administer Pulmozyme. Each Pulmozyme treatment, dosed QD or BID, requires the following items1:
Administer Pulmozyme via a vibrating mesh nebulizer, or via a jet nebulizer connected to an air compressor with an adequate air flow and equipped with a mouthpiece or suitable face mask.
The patient should follow the Manufacturer’s Instructions for Use on the use, maintenance, and replacement of the equipment, including cleaning and disinfection procedures.
For additional information, refer to recommended nebulizer Manufacturer’s Instructions for Use.
Jet Nebulizer* | Compressor |
---|---|
Hudson T Up-draft II® | Pulmo-Aide® or legally marketed compressor of identical pressure and flow rate (maximum 30 psi, 12 LPM). |
Marquest Acorn II® | |
PARI LC® Plus | PARI PRONEB® or legally marketed compressor of identical pressure and flow rate (maximum 24 psi, 9 LPM). |
ƗPARI BABY™ | |
Durable Sidestream® | MOBILAIRE™, Porta-NEB® or legally marketed compressor of identical pressure and flow rate (maximum 45 psi, 7 LPM). |
eRapid® Nebulizer Systemǂ |
Innospire Go |
Pulmogine Vibrating Mesh Nebulizer |
AireHealth Nebulizer™ |
Intelligent Mesh Nebulizer |
*Follow the selected nebulizer manufacturer’s instruction manual.
ƗPatients who are unable to inhale or exhale orally throughout the entire nebulization period may use the PARI BABY™ nebulizer.
ǂConsisting of the eRapid® Nebulizer Handset with eBase™ Controller. Avoid use in patients who need a mask to inhale PULMOZYME.
A step-by-step guide to taking Pulmozyme, including a list of equipment needed.
Patients may want to consider what conveniences they need. For example, nebulizers/compressors may have different delivery times and cleaning instructions.
Certain nebulizers are designed especially for younger children and have features such as a mask instead of a mouthpiece.
Costs, out-of-pocket expenses, and insurance coverage can vary.
Pulmozyme (dornase alfa) [package insert]. South San Francisco, CA: Genentech, Inc; 2024.
Pulmozyme (dornase alfa) [package insert]. South San Francisco, CA: Genentech, Inc; 2024.
Harms HK, Matouk E, Tournier G, et al; DNase International Study Group. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol. 1998;26(3):155-161.
Harms HK, Matouk E, Tournier G, et al; DNase International Study Group. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol. 1998;26(3):155-161.
Chmiel JF, Konstan MW. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med. 2005;4(4):255-273.
Chmiel JF, Konstan MW. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med. 2005;4(4):255-273.
Puchelle E, de Bentzmann S, Zahm JM. Physical and functional properties of airway secretions in cystic fibrosis—therapeutic approaches. Respiration. 1995;62(suppl 1):2-12.
Puchelle E, de Bentzmann S, Zahm JM. Physical and functional properties of airway secretions in cystic fibrosis—therapeutic approaches. Respiration. 1995;62(suppl 1):2-12.
King M. Mucolytics and mucus clearance. In: Rubin BK, van der Schans CP, eds. Therapy for Mucus-Clearance Disorders. New York, NY: Marcel Dekker Inc; 2004:201-224.
King M. Mucolytics and mucus clearance. In: Rubin BK, van der Schans CP, eds. Therapy for Mucus-Clearance Disorders. New York, NY: Marcel Dekker Inc; 2004:201-224.
Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med. 2012;10:88.
Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med. 2012;10:88.
Drug development pipeline. Cystic Fibrosis Foundation website. https://www.cff.org/trials/pipeline. Accessed August 17, 2020.
Drug development pipeline. Cystic Fibrosis Foundation website. https://www.cff.org/trials/pipeline. Accessed August 17, 2020.
Research milestones. Cystic Fibrosis Foundation website. https://www.cff.org/about-us/our-history. August 17, 2020.
Research milestones. Cystic Fibrosis Foundation website. https://www.cff.org/about-us/our-history. August 17, 2020.
Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642.
Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642.
Data on file. Genentech, a member of the Roche Group.
Data on file. Genentech, a member of the Roche Group.
Cystic Fibrosis Foundation Patient Registry 2016 Annual Data Report. Bethesda, MD. ©2017 Cystic Fibrosis Foundation.
Cystic Fibrosis Foundation Patient Registry 2016 Annual Data Report. Bethesda, MD. ©2017 Cystic Fibrosis Foundation.
Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009;180(2):146-152.
Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009;180(2):146-152.
Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368(21):1963-1970.
Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368(21):1963-1970.
Bakker EM, Volpi S, Salonini E, et al. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial. Pediatr Pulmonol. 2020;49(2):154-161.
Bakker EM, Volpi S, Salonini E, et al. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial. Pediatr Pulmonol. 2020;49(2):154-161.
Trikafta [Package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2021.
Trikafta [Package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2021.
Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212)1940-1948.
Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212)1940-1948.
Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809-1819.
Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809-1819.
Pulmozyme Instructions for Use. South San Francisco, CA: Genentech, Inc; 2024.
Pulmozyme Instructions for Use. South San Francisco, CA: Genentech, Inc; 2024.
Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680-689.
Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680-689.
Clancy JP. Ongoing research into CFTR modulation. Adv Stud Med. 2010;10(1):14-18.
Clancy JP. Ongoing research into CFTR modulation. Adv Stud Med. 2010;10(1):14-18.
Treatments and therapies. Cystic Fibrosis Foundation website. https://www.cff.org/Life-With-CF/Treatments-and-Therapies/. Accessed July 22, 2021.
Treatments and therapies. Cystic Fibrosis Foundation website. https://www.cff.org/Life-With-CF/Treatments-and-Therapies/. Accessed July 22, 2021.
Medications. Cystic Fibrosis Foundation website. https://www.cff.org/Life-With-CF/Treatments-and-Therapies/Medications/. Accessed July 22, 2021.
Medications. Cystic Fibrosis Foundation website. https://www.cff.org/Life-With-CF/Treatments-and-Therapies/Medications/. Accessed July 22, 2021.
Non-US Residents visit: Pulmozyme.global
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.